Methods of reducing small, dense ldl particles

Abstract

The present invention provides methods for increasing LDL particle size.

1 .- 20 . (canceled) 
     
     
         21 . A method of changing the LDL particle size pattern in a human having LDL particle size pattern I or B, from pattern I to pattern A, or from pattern B to pattern I or A, comprising the administration of a therapeutically effective amount of a compound of the formula 
       
         
           
           
               
               
           
         
       
       or a salt thereof. 
     
     
         22 . The method of  claim 21 , where the administration lowers the level of LDL-III particles of the human. 
     
     
         23 . The method of  claim 21 , where the administration lowers the level of LDL-IV particles of the human. 
     
     
         24 . The method of  claim 21 , where the human has an LDL particle size pattern A after 10 days of administration. 
     
     
         25 . The method of  claim 21 , where the human has an LDL particle size pattern B prior to administration. 
     
     
         26 . The method of  claim 21 , where the Apoplipoprotein B-100 blood level of the human is reduced by at least 10% after 10 days of administration. 
     
     
         27 . The method of  claim 21 , where the cholesterol absorption of the human is reduced by at least 5% after 10 days of administration. 
     
     
         28 . The method of  claim 27 , where the cholesterol absorption of the human is reduced by at least 10% after 10 days of administration. 
     
     
         29 . The method of  claim 28 , where the cholesterol absorption of the human is reduced by at least 20% after 10 days of administration. 
     
     
         30 . The method of  claim 21 , where the cholesterol synthesis of the human is reduced by at least 5% after 10 days of administration. 
     
     
         31 . The method of  claim 30 , where the cholesterol synthesis of the human is reduced by at least 10% after 10 days of administration. 
     
     
         32 . The method of  claim 31 , where the cholesterol synthesis of the human is reduced by at least 20% after 10 days of administration. 
     
     
         33 . The method of  claim 21 , further comprising administration of a statin. 
     
     
         34 . The method of  claim 33 , where the statin is atorvastatin. 
     
     
         35 . The method of  claim 21 , where the human has diabetes. 
     
     
         36 . The method of  claim 21 , where the human is insulin resistant. 
     
     
         37 . The method of  claim 21 , where the human has atherosclerosis. 
     
     
         38 . The method of  claim 21 , where the human has metabolic syndrome. 
     
     
         39 . The method of  claim 21 , where the human has dyslipidemia.